Romidepsin: a histone deacetylase inhibitor for refractory cutaneous T-cell lymphoma (Q38042561)

27 August 2017

title

Romidepsin: a histone deacetylase inhibitor for refractory cutaneous T-cell lymphoma (English)

1 reference

27 August 2017

Miryoung Kim

1

1 reference

27 August 2017

Lisa A Thompson

series ordinal

2

1 reference

27 August 2017

Sarah D Wenger

series ordinal

3

1 reference

27 August 2017

Cindy L O'Bryant

series ordinal

4

1 reference

27 August 2017

language of work or name

English

0 references

publication date

11 September 2012

1 reference

Annals of Pharmacotherapy

27 August 2017

published in

1 reference

27 August 2017

volume

46

1 reference

27 August 2017

issue

10

1 reference

27 August 2017

page(s)

1340-1348

1 reference

Incidence of cutaneous T-cell lymphoma in the United States, 1973-2002.

27 August 2017

cites work

1 reference

Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases

21 January 2018

1 reference

Joint British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous T-cell lymphomas.

21 January 2018

1 reference

EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome.

21 January 2018

1 reference

Sézary syndrome: diagnosis, prognosis, and critical review of treatment options

21 January 2018

1 reference

Update on treatment of cutaneous T-cell lymphoma

21 January 2018

1 reference

Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sézary syndrome).

21 January 2018

1 reference

Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma

21 January 2018

1 reference

The Emerging Role of Histone Deacetylase Inhibitors in Treating T-cell Lymphomas

21 January 2018

1 reference

Romidepsin: a novel histone deacetylase inhibitor for cancer

21 January 2018

1 reference

Histone deacetylase inhibitors in lymphoma

21 January 2018

1 reference

Romidepsin: in the treatment of T-cell lymphoma

21 January 2018

1 reference

Emerging role of the histone deacetylase inhibitor romidepsin in hematologic malignancies

21 January 2018

1 reference

Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma

21 January 2018

1 reference

Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma

21 January 2018

1 reference

A phase I trial of depsipeptide (FR901228) in patients with advanced cancer.

21 January 2018

1 reference

Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma

21 January 2018

1 reference

Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma

21 January 2018

1 reference

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

21 January 2018

1 reference

Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results

21 January 2018

1 reference

Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma

21 January 2018

1 reference

The treatment of cutaneous T-cell lymphoma with photopheresis

21 January 2018

1 reference

Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients

21 January 2018

1 reference

Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome.

21 January 2018

1 reference

Prospective multicenter study of pegylated liposomal doxorubicin treatment in patients with advanced or refractory mycosis fungoides or Sézary syndrome

21 January 2018

1 reference

Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma

21 January 2018

1 reference

Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma

21 January 2018

1 reference

Current and emerging treatment strategies for cutaneous T-cell lymphoma

21 January 2018

1 reference

Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sézary syndrome: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.

21 January 2018

1 reference

Histone deacetylase inhibitors and demethylating agents: clinical development of histone deacetylase inhibitors for cancer therapy

21 January 2018

1 reference

New drugs: pitavastatin calcium, vigabatrin, and romidepsin

21 January 2018

1 reference

Targeting histone deacetyalses in the treatment of B- and T-cell malignancies

21 January 2018

1 reference

Characterisation of the novel apoptotic and therapeutic activities of the histone deacetylase inhibitor romidepsin

21 January 2018

1 reference

Histone deacetylase inhibitors: emerging mechanisms of resistance.

21 January 2018

1 reference

Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma

21 January 2018

1 reference

Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy

21 January 2018

1 reference

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.1R036

1 reference

27 August 2017

1 reference